Anavex Life Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference 2025GlobeNewsWire • 09/02/25
Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Established Precise Autophagy Mechanism with BlarcamesineGlobeNewsWire • 08/26/25
Anavex Life Sciences Announces New Publication in Medical Journal: Blarcamesine Prevented Cognitive Impairment in Animal Model of Alzheimer's DiseaseGlobeNewsWire • 08/20/25
Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business UpdateGlobeNewsWire • 08/12/25
Anavex Life Sciences to Announce Fiscal 2025 Third Quarter Financial Results on Tuesday, August 12, 2025GlobeNewsWire • 08/05/25
Anavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer's DiseaseGlobeNewsWire • 07/31/25
Are You Looking for a Top Momentum Pick? Why Anavex Life Sciences (AVXL) is a Great ChoiceZacks Investment Research • 07/10/25
ANAVEX SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Long-Term Investors to Contact the FirmGlobeNewsWire • 06/16/25
The Unusual Effects Of Anavex's Blarcamesine On Alzheimer's Disease (Upgrade)Seeking Alpha • 05/15/25
Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business UpdateGlobeNewsWire • 05/13/25
Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025GlobeNewsWire • 05/06/25
Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of SchizophreniaGlobeNewsWire • 05/01/25
Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory BoardGlobeNewsWire • 04/23/25
Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer's Disease and Related Disorders in the Middle EastGlobeNewsWire • 04/21/25
Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer's DiseaseGlobeNewsWire • 04/05/25
Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 03/31/25
Anavex Life Sciences to Present at the 45th Annual TD Cowen Health Care ConferenceGlobeNewsWire • 02/24/25